JNJ.N
Latest Trade
145.24USDChange
0.16(+0.11%)Volume
1,098,788Today's Range
-
147.4752 Week Range
-
157.00As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 145.08 |
|---|---|
Open | 145.74 |
Volume | 1,098,788 |
3M AVG Volume | 126.80 |
Today's High | 147.47 |
Today's Low | 144.35 |
52 Week High | 157.00 |
52 Week Low | 109.17 |
Shares Out (MIL) | 2,632.82 |
Market Cap (MIL) | 382,391.30 |
Forward P/E | -- |
Dividend (Yield %) | 2.78 |
J&J Prepares To Resume Phase 3 Ensemble Trial Of Janssen Covid-19 Vaccine Candidate In U.S.
Genmab Announces IFM, Hovon And Janssen Achieve Positive Topline Results In Second Part Of Phase 3 Cassiopeia Study Of Daratumumab In Multiple Myeloma At Pre-Planned Interim Analysis
Janssen Receives Positive CHMP Opinion For Long-Acting Regimen For The Treatment Of Hiv
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry
Biotechnology & Drugs
Contact Info
1 Johnson And Johnson Plz
NEW BRUNSWICK, NJ
08933-0001
United States
+1.732.5242455
https://www.jnj.com/Executive Leadership
Alex Gorsky
Chairman of the Board, Chief Executive Officer
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 23.24 |
|---|---|
Price To Sales (TTM) | 4.73 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | 20.76 |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
U.S. Vice President Mike Pence planned to press ahead with campaigning on Sunday, visiting the battleground state of North Carolina after multiple aides tested positive for COVID-19, keeping the pandemic front and center in the presidential race.
AstraZeneca Plc <AZN.L> has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson <JNJ.N> is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.
Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.
Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter.
* JOHNSON & JOHNSON CORONAVIRUS VACCINE TRIAL, PAUSED DUE TO AN UNEXPLAINED ILLNESS IN A PARTICIPANT, WILL RESUME VERY SOON - WASHINGTON POST Source: https://wapo.st/2HsTJwc Further company coverage:
Pennsylvania's highest court on Wednesday upheld a $12.5 million verdict awarded to an Indiana woman who accused Johnson & Johnson subsidiary Ethicon of making defective pelvic mesh that injured her, rejecting the company's argument that the state's courts lacked jurisdiction...
* OPERATION WARP SPEED CHIEF SLAOUI EXPECTS U.S. TRIALS OF VACCINES MADE BY ASTRAZENECA AND JOHNSON & JOHNSON TO RESUME AS SOON AS THIS WEEK-BLOOMBERG Source text : https://bloom.bg/3dOr9RT Further company coverage:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
AstraZeneca Plc's <AZN.L> COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.
GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.
The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.
GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.
Asian equities slipped on Wednesday as halted COVID-19 vaccine trials and an impasse in U.S. fiscal aid package talks soured risk appetite, while the greenback held on to gains as demand firmed for safe-harbour assets.
Asian equities were set to slip on Wednesday as halted COVID-19 vaccine trials and an elusive U.S. stimulus agreement weighed on investor sentiment, while the dollar rose from Tuesday's three-week low as demand firmed for safe-haven assets.
The U.S. dollar strengthened on Tuesday as investors turned cautious after a Johnson & Johnson COVID-19 study was paused and as hopes dimmed that a fiscal stimulus package could be reached before the presidential election.
The U.S. dollar rose from a three-week low on Tuesday while shares in Europe and the United States eased, as news of a pause in Johnson & Johnson's COVID-19 vaccine trial led investors to take stock of recent rallies before chasing further gains.
Johnson & Johnson <JNJ.N> said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.
Johnson & Johnson said on Tuesday it would take a few days at least to hear from a safety monitoring panel about its review of the company's late-stage COVID-19 vaccine trial after announcing that the large study had been paused due to an unexplained illness in one participant...
Johnson & Johnson <JNJ.N> said on Tuesday it would take at least a few days for an independent safety panel to evaluate an unexplained illness of a study participant that led to a pause in the company's COVID-19 vaccine trial.
Johnson & Johnson on Tuesday said it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing the total amount it would pay to $5 billion.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.